Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients

12 Jun 2007

Abstract excerpt

The Assessment of Lescol in Renal Transplantation clinical trial demonstrated the efficacy of fluvastatin in reducing cardiovascular (CV) disease in renal transplant recipients. The study included a voluntary pharmacogenetic component, enrolling 1,404 patients, which allowed association testing of baseline measures and longitudinal analysis of the 707 fluvastatin-treated and 697 placebo-treated individuals. A...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatitis C virus research
Share to Lipoproteins and Cardiovascular Health
Share to Peroxisome Proliferator-Activated Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17563401
DOI: 10.1194/jlr.m700076-jlr200

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipientsPMID 17563401Read ↗

An association study of 43 SNPs in 16 candidate genes with atorvastatin response.Semantic proximity Read ↗

Pharmacogenetic study of statin therapy and cholesterol reduction.Semantic proximity Read ↗

Pharmacogenomics of statin response.Semantic proximity Read ↗

Genetic polymorphisms in emerging cardiovascular risk factors and response to statin therapy.Semantic proximity Read ↗

The impact of immune gene polymorphisms in kidney and liver transplantation.Semantic proximity Read ↗

Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia.Semantic proximity Read ↗

Genetic determinants of the response to bezafibrate treatment in the lower extremity arterial disease event reduction (LEADER) trial.Semantic proximity Read ↗

Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy.Semantic proximity Read ↗

CYP2C9 and ABCG2 polymorphisms as risk factors for developing adverse drug reactions in renal transplant patients taking fluvastatin: a case-control study.Semantic proximity Read ↗

The association of common SNPs and haplotypes in the CETP and MDR1 genes with lipids response to fluvastatin in familial hypercholesterolemia.Semantic proximity Read ↗

Polymorphisms in genes involved in vasoactive eicosanoid synthesis affect cardiovascular risk in renal transplant recipients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.